Immunic (IMUX) Preferred Stock Liabilities (2013)

Immunic's (IMUX) quarterly Preferred Stock Liabilities came in at $82.1 million in Q4 2013.

Immunic (IMUX) Preferred Stock Liabilities (2013) Analysis & Trends

Immunic has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $82.1 million for Q4 2013.

Preferred Stock Liabilities for Q4 2013 came in at $82.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was $82.1 million (changed N/A YoY), and the FY2013 annual result was $82.1 million, changed N/A from the prior year.
Preferred Stock Liabilities came in at $82.1 million for Q4 2013 at Immunic.
In the past five years, Preferred Stock Liabilities ranged from a high of $82.1 million in Q4 2013 to a low of $82.1 million in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	-
9	Abivax	94.26 Bn	94.26 Bn	-	-
10	Immunic	384.84 Mn	198.21 Mn	-	-

Download Data

Date	Value
Dec 31, 2013	82.12 Mn